Skinvisible Q3 10-Q: $4,370 Cash, $5.75M Working Capital Deficit, Going Concern Reiterated
SKVI has more than doubled off its 52-week low of $0.055 on light trading volume (0.3× avg).
Summary
Skinvisible's Q3 10-Q shows $4,370 of cash, a $5,753,628 working capital deficit and a reiterated going concern warning, with related-party loans the only source of funding. Two notes are in default, and 82,981,326 shares remain issuable under convertible notes versus 5,403,843 outstanding.
Key Events · Earnings and Guidance · SKVI
-
Going Concern Doubt Reiterated
Management states substantial doubt about the ability to continue as a going concern within one year, citing a $778,401 nine-month net loss and cumulative losses of $41,788,577 since inception.
-
Cash of $4,370 Against $5.79M Current Liabilities
Working capital deficit widened to $5,753,628 at September 30, 2026 from $4,990,414 at December 31, 2025; total liabilities were $11,157,493 against total assets of $116,311.
-
Funding Comes Only From Related-Party Loans
Financing activities provided $90,901, entirely from related-party loans; no common shares were issued in the nine months, and operations used $89,151 of cash.
-
Two Notes in Default
A $10,000 promissory note due one year from February 7, 2025 and a $352,075 convertible note from the 2019 renegotiation remain unpaid and in default as of September 30, 2026.
Analysis · SKVI · Life Sciences
Skinvisible closed September 30, 2026 with $4,370 of cash against $5,785,090 of current liabilities, leaving a $5,753,628 working capital deficit that widened from $4,990,414 at December 31, 2025. Related-party loans of $90,901 were the only cash coming in, while operations burned $89,151 and no equity was sold. Management repeats that substantial doubt exists about the company's ability to continue as a going concern and says it needs a private equity offering to fund operations, with no assurance it can raise the money. Two notes remain in default. The equity is deeply underwater, with a total stockholders' deficit of $11,041,182, and 82,981,326 additional shares are issuable under convertible notes against 5,403,843 shares outstanding, so any conversion would swamp existing holders.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKVI was trading at $0.18 on OTC in the Life Sciences sector, with a market capitalization of approximately $972.7K. The 52-week trading range was $0.06 to $0.90. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.